GI Oncology Now

The leading medical news resource for practicing oncologists and health care providers treating gastrointestinal malignancies

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

MEK Inhibitor-Based Therapy for Metastatic Pancreatic Cancer With KRAS G12R Mutations

Drs. Elizabeth Auckley, Stephanie Yohay, and Mandana Kamgar of the Medical College of Wisconsin discuss their research on the efficacy of MEK inhibitor-based therapy for metastatic pancreatic ductal adenocarcinoma in this three-part interview.

In the first part of this discussion, the KRAS G12R mutation is analyzed against other KRAS alterations in pancreatic adenocarcinoma, and key research findings are shared.

Latest News

ctDNA Detection Outperforms Standard Surveillance in Predicting BTC Recurrence

Emily MenendezBile Duct Cancer | February 20, 2025

Among 16 patients with confirmed recurrence, ctDNA accurately identified recurrence in 15 patients.

KRAS G12R Mutations in Pancreatic Cancer: Research Considerations and Next Steps

Elizabeth Auckley, MDPancreatic Cancer | February 14, 2025

Challenges in designing and conducting clinical trials for patients with metastatic pancreatic ductal cancer are discussed.

MEK Inhibitors for Mutated Pancreatic Cancer: Safety, Efficacy, and Combinations

Elizabeth Auckley, MDPancreatic Cancer | February 14, 2025

The efficacy and safety of MEK inhibitors are compared to chemotherapy and other targeted therapies.

Investigating Novel Immunotherapy Combinations for Advanced Gastric and Esophageal Cancers

Samuel Cytryn, MDGastric Cancer | February 8, 2025

Dr. Cytryn summarizes a trial in progress investigating a novel immunotherapy combination for gastroesophageal adenocarcinoma

What’s Next for Adjuvant Therapy in Liver Cancer? Reflections on IMbrave050 and Beyond

Richard S. Finn, MDLiver Cancer | February 7, 2025

Drs. Finn and Yopp discuss the challenges of defining high-risk patient populations in adjuvant therapy trials for HCC.

CheckMate 9DW Expanded Analyses: Nivo/Ipi Versus Len/Sor as 1L Therapy for uHCC

Christopher Lieu, MDLiver Cancer | February 6, 2025

Nivolumab plus ipilimumab provided a higher OS and ORR rate, supporting the combination as a potential standard of care.

CheckMate 8HW: Nivo/Ipi Versus Nivo Alone for MSI-H/dMMR mCRC

Christopher Lieu, MDColorectal Cancer | February 5, 2025

The combination was shown to provide a 71% response rate, pointing to a new potential treatment for this patient population.

BREAKWATER: New Standard of Care Frontline Regimen for BRAF V600E-Mutant mCRC

Christopher Lieu, MDColorectal Cancer | February 5, 2025

With an OS rate of about 80%, encorafenib and cetuximab with FOLFOX may serve as a new FDA-approved frontline regimen.

Tumor Differentiation and Survival Outcomes in Gastric Cancer: The Role of Neoadjuvant Chemotherapy

Emily MenendezGastric Cancer | February 5, 2025

Patients with locally advanced GC who achieved pCR after NAC had significantly better survival outcomes.

BREAKWATER Study Shows Superior ORR With Encorafenib-Based Regimen in BRAF V600E-Mutant mCRC

Emily MenendezColorectal Cancer | February 4, 2025

Encorafenib with cetuximab was approved by the FDA in 2024 for previously treated patients with BRAF V600E-mutant mCRC.

Roundtable Discussions

Oncology Brothers Event Coverage

Advancements in Oncology: GI Cancer

GI Oncology Now has exclusive coverage of Advancement in Oncology: Today’s Data for Tomorrow’s Practice, the first event co-hosted by The Oncology Brothers and Mashup Media. Review the breakthrough data on gastrointestinal cancers presented at the event and insights from esteemed experts that bridge the gap between research and practice for community oncologists.

Conference Coverage

ASCO GI Symposium 2025

GI Oncology Now reviews education from ASCO GI 2025, featuring the latest advances in the field of GI cancer research.

ASCO GI Symposium 2025: Focus on Liver Cancer

Coverage of the 2025 ASCO GI Symposium, with a focus on liver cancer

ESMO 2024: GI Oncology Now

The latest news and research updates in GI cancer treatment from the ESMO Congress 2024

ASCO 2024: GI Oncology Now

The latest news and research updates in GI cancer treatment from the ASCO 2024 Annual Meeting

ASCO GI Symposium 2024

GI Oncology Now reviews education from ASCO GI 2024, featuring the latest advances in the field of GI cancer research.

Expert Interviews

Benjamin Weinberg, MD, FACPEditor | Associate Professor of Medicine at Lombardi Comprehensive Cancer Center

Zev Wainberg, MD, MScEditor | Co-Director of Gastrointestinal Oncology at the University of California, Los Angeles